Oncology

Latest News

In the phase 3 IMforte trial, patients with extensive-stage small cell lung cancer experienced clinically meaningful benefits with maintenance lurbinectedin plus atezolizumab vs atezolizumab. | Image credit: appledesign - stock.adobe.com

Lurbinectedin Plus Atezolizumab Maintenance Shows Improved Survival vs Atezolizumab in SCLC

By Rose McNulty

May 22nd 2025

Patients with extensive-stage small cell lung cancer (SCLC) experienced clinically meaningful benefits with lurbinectedin plus atezolizumab vs atezolizumab in the phase 3 IMforte trial, according to findings being presented at the ASCO Annual Meeting.

AJMC Q&A with Eileen Peng, PharmD | Background image credit: ipopba - stock.adobe.com

The Role of Pharmacists Expands Beyond Dispensing for Novel Cancer Therapies: Eileen Peng, PharmD

By Laura Joszt, MA
Eileen Peng, PharmD

May 21st 2025

Future validation studies with a larger sample size are warranted to ensure the technique will be useful in a clinical setting. | Image credit: Artur Wnorowski - stock.adobe.com

Novel, Noninvasive Skin Cancer Detection Method Shows Promise

By Jared Kaltwasser

May 18th 2025

FDA Approved | Image credit: chrisdorney – stock.adobe.com

Teliso-V Approved to Treat Advanced NSCLC With High c-Met Protein Overexpression

By Hayden E. Klein

May 14th 2025

While CTCs were identified regardless of disease stage, the current study identified large variations in the presence of CTCs between nonmetastatic and metastatic disease | Image Credit: Innovative Creation - stock.adobe.com

Flow Cytometry Can Reliably Identify CTC in Melanoma

By AJMC Contributor

May 14th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

February 8th 2016

PhRMA Plans Targeted Ad Campaign in Wake of Focus on Drug Costs

The ads will be targeted at about 7000 "influencers" including lawmakers who could control whether drug prices are regulated. Many have called for Medicare to gain the right to negotiate drug prices.

February 8th 2016

Evolving Practices in Managing Costly Immunotherapy

Carina Verdier Dolan, PharmD, BCOP

To address the nationwide concern of costly immunotherapy agents, this article features health system inpatient and outpatient strategies that can help mitigate their costs.

February 8th 2016

PCPs Diligent With Following USPSTF Recommendations on PSA Testing

Surabhi Dangi-Garimella, PhD

Using data gathered from the National Ambulatory Medical Care Survey, the authors of a JAMA Internal Medicine study identified a significant decrease in PSA testing referrals by primary care physicians compared with urologists.

February 7th 2016

What We Know About California's Right-to-Die Law, Except When It Takes Effect

A quirk in California law means the law that Governor Jerry Brown signed with much fanfare last fall hasn't taken effect yet, even though its passage is having ripple effects.

February 7th 2016

Considering the Burden on Family Caregivers

A deeper understanding of the interdependencies among the patients, family caregivers, and service providers revealed that if general practice teams intervene early, they may be more likely meet patients’ needs in the end-of-life care process.

February 6th 2016

Lipegfilgrastim a Possible Alternative for Managing Chemotherapy-Induced Neutropenia

The novel molecule lipegfilgrastim has been shown to be relatively equivalent to pegfilgrastim in the management of chemotherapy-induced neutropenia among patients with breast cancer.

February 5th 2016

A New Biosimilar to Remicade in the Fray

Scientists at the FDA have provided their recommendation to be submitted to an independent medical advisory panel that will decide the fate of Remsima.

February 5th 2016

Cancer Treatment Financially Devastating in Young Adult Survivors, Says Samfund Study

Surabhi Dangi-Garimella, PhD

The paper in Cancer Medicine finds that cancer has a devastating and age-specific impact on the finances of young adult survivors.

February 5th 2016

Where Does Immuno-Oncology Fit in a Value-Based Care Delivery Model?

Bruce Feinberg, DO

Advances made in the field of immuno-oncology (I-O) in 2015 have greatly expanded our understanding of I-O and added more complexity to its value assessment.

February 5th 2016

The Fight of Our Lives: Confronting the Unmet Need in Lung Cancer

Bonnie J. Addario

Supporting, funding, and protecting the research and development of new medicines and new treatments is more critical, now than ever, to provide better treatments and better outcomes to all cancer patients.

February 4th 2016

High Risks, High Costs Associated With Febrile Neutropenia in Metastatic Cancer

Data from 2 large studies of patients with metastatic disease who underwent myelosuppressive chemotherapy found that febrile neutropenia occurred in approximately 13% to 21% of patients. Associated costs of febrile neutropenia were found to range from $16,000 to $19,000 per episode for most hospitalized patients.

February 4th 2016

ASCO Highlights the Year in Oncology Advances

Laura Joszt, MA

The annual Clinical Cancer Advances report from the American Society of Clinical Oncology highlights the accomplishments made in the last year in the fight against cancer.

February 4th 2016

On World Cancer Day, Stories of Courage and Support

Surabhi Dangi-Garimella, PhD

On World Cancer Day, The American Journal of Managed Care would like to acknowledge the determination of cancer survivors and the support provided by various organizations to patients and their families.

February 4th 2016

Immuno-Oncology 2016 and Beyond: The Opportunities, Challenges, and Risks

Michael V. Seiden, MD, PhD

The translation of immuno-oncology agents from the research to the practice arena may provide significant clinical benefit to patients with difficult-to-treat malignancies. The further development and marketing of these agents could escalate the discussion on care equity in a time of constrained resources.

February 3rd 2016

Fight With or Adapt to Rising Drug Prices? Economists Debate at the AcademyHealth Conference

Surabhi Dangi-Garimella, PhD

Rising drug prices, the effect on the healthcare system, consumer push-back, and possible solutions were debated by the expert panel.

February 3rd 2016

Molecular Testing Patterns in Metastatic Non—Small Cell Lung Cancer

Elizabeth MacLean, PharmD Anthony Louder, PhD, RPh Kim Saverno, PhD, RPh Gregory Smith, BA Jack Mardekian, PhD Cari Bruins, PharmD Melea Ward, PharmD, PhD Robert Sweetman, MD Margaret Pasquale, PhD

Assessment of the timing of histologic and molecular testing indicates that testing occurred prior to treatment initiation for most patients with metastatic nonâ€”small cell lung cancer.

February 2nd 2016

Rationing Care in Times of Drug Shortages

Surabhi Dangi-Garimella, PhD

Pediatric oncologists from across the country covened a task force to develop an ethical framework that guides decisions on allocation based on curability, prognosis, and the incremental importance of a drug to a patient’s outcome

February 2nd 2016

Comparing End-of-Life Care for Cancer Patients in 7 Developed Countries

Among 7 developed countries, the United States has the lowest proportion of deaths that occur in the hospital and the lowest number of days spent in the hospital during the last 6 months of life.

February 1st 2016

How Successful Will Gleevec's Generic Competitor Be?

Surabhi Dangi-Garimella, PhD

The generic manufacturer may try to maximize profits during the initial exclusivity period, says an expert from a leading health plan.

February 1st 2016

Will New Evidence for Proton Radiotherapy Swing Payers?

Surabhi Dangi-Garimella, PhD

With increasing evidence of comparable efficacy and reduced toxicity of proton beam therapy, payers may have to reevaluate coverage policies.

February 1st 2016

What We're Reading: Cancer Moonshot Creates Hard Feelings With Some Researchers

What we're reading, February 1, 2016: some medical researchers disagree with sharing raw data used in their research; the medical community is torn on whether or not the annual checkup is worthwhile; and Donald Trump vows to extend healthcare coverage to the lower class.

January 31st 2016

Early Palliative Care for Cancer Patients With More Comorbidities Reduces Cost

Providing cancer patients with multiple life-threatening conditions with earlier palliative care consultation can be helpful in bringing down healthcare spending in enormous proportions, according to a new study published in Health Affairs.

This Week in Managed Care: January 30, 2016

January 30th 2016

This Week in Managed Care: January 30, 2016

Top managed care news of the week includes new recommendation to screen all adults for depression, new issue of The American Journal of Managed Care places attention on mental health care, and Donald Trump calls for Medicare to negotiate drug prices.

January 30th 2016

Tbo-Filgrastim Can Replace Filgrastim During ASCT in Myeloma and Lymphoma

A study presented at the annual meeting of the American Society of Hematology concluded that tbo-filgrastim is similar to filgrastim for ASCT mobilization in patients with MM or NHL.

January 29th 2016

Study Identifies Disparity in Survival of AYA Hodgkin Lymphoma

Surabhi Dangi-Garimella, PhD

Mortality in adolescent and young adult Hodgkin lymphoma patients is significantly affected by ethnic and socioeconomic factors, as well as insurance status, according to a new study published in Cancer Epidemiology, Biomarkers & Prevention.

January 29th 2016

Do Hematologists Believe APMs Afford Fair Value? An Open Discussion at ASH

Surabhi Dangi-Garimella, PhD

At the annual meeting of the American Society of Hematology, physicians gathered to discuss the impact of alternate payment models on clinical practice.

January 29th 2016

Does Geographic Location Influence Healthcare Utilization in Children With Lymphoma?

Surabhi Dangi-Garimella, PhD

A study presented at the 57th meeting of the American Society of Hematology finds that distance from the site of care could could adversely affect outcomes in children with acute lymphoblastic leukemia and acute myeloid leukemia.

January 29th 2016

Healthcare Utilization in Children With Sickle Cell Disease

Surabhi Dangi-Garimella, PhD

At the annual meeting of the American Society of Hematology, researchers from the Aflac Cancer and Blood Disorders Center presented analysis evaluating the factors that influence health outcomes in children with sickle cell disease.

January 29th 2016

5 Things to Know About Clinical Pathways

Surabhi Dangi-Garimella, PhD

Learn where clinical care pathways stand today and what the future holds with respect to developing and implementing them.

January 28th 2016

FDA Advocates for Diversity in Clinical Trials

Surabhi Dangi-Garimella, PhD

The FDA has created the Drug Trial Snapshot, which provides details on the demographic profiles of participants in clinical trials of approved drugs.

...

109 110 111 112 113 114 115 116 117

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions